Equity Overview
Price & Market Data
Price: $26.70
Daily Change: +$0.34 / 1.27%
Daily Range: $24.86 - $26.78
Market Cap: $5,413,956,096
Daily Volume: 719,596
Performance Metrics
1 Week: 3.74%
1 Month: 2.23%
3 Months: 12.28%
6 Months: 79.49%
1 Year: 30.07%
YTD: 4.64%
Company Details
Employees: 362
Sector: Health technology
Industry: Biotechnology
Country:
Details
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.